Therefore, the SUMO pathway appears as a regulatory mechanism and a potential therapeutic target for regulating DAT function, dopamine clearance at the presynaptic terminal, and dopamine signaling in the pathophysiology of autism spectrum disorders, ADHD, and DTDS. Here, SLC6A3 is linked to autism spectrum disorder.